Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study

Bibliographic Details
Main Authors:	Garcia-Manero, G, Daver, N, Xu, J, Chao, M, Chung, T, Tan, A, Wang, Y, Wei, A, Vyas, P, Sallman, D
Format:	Conference item
Language:	English
Published:	Elsevier 2021

Similar Items